Comparison · NCT00724893-68a39148
Stage 1 Participants vs Stage 2 Participants: Number of Participants Discontinued From Study Treatment Due to Adverse Events (Stage 1 and Stage 2)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Stage 1 Participants vs Stage 2 Participants: Number of Participants Discontinued From Study Treatment Due to Adverse Events (Stage 1 and Stage 2). Trial comparisons, record NCT00724893-68a39148. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00724893-68a39148
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0584 | 0.0469 | 0.0725 | wilson | |
| Risk in group 2 | 0.126 | 0.108 | 0.147 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0675 | -0.0911 | -0.0446 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.464 | 0.355 | 0.606 | log | |
| Odds ratio, group 1 over group 2 | 0.43 | 0.322 | 0.576 | log | |
| Number needed to treat, for one fewer participant with the outcome on Stage 1 Participants than on Stage 2 Participants | 14.8 | 11 | 22.4 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Stage 1 Participants | Participants with chronic hepatitis C (CHC) receiving PegIFN-2b using Redipen™ formulation (1.5 mcg/kg) once weekly and ribavirin capsules (800-1400 mg) daily according to routine medical practice at participating study sites. | 76 | 1,302 | OG000 |
| Group 2 | Stage 2 Participants | Participants with CHC Genotype 1 receiving PegIFN-2b using Redipen™ formulation (1.5 mcg/kg) once weekly and ribavirin capsules (800-1400 mg) daily according to routine medical practice at participating study sites. | 142 | 1,128 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Discontinued From Study Treatment Due to Adverse Events (Stage 1 and Stage 2)
- Description
- An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment
- Time frame
- Up to 48 weeks
- Population
- All participants who took at least one dose of study medication (ITT Population)
Source ClinicalTrials.gov
Trial
- Title
- Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)
- NCT number
- NCT00724893
- Phases
- Conditions
- Hepatitis C, Chronic, Hepatitis C
- Interventions
- PegIFN-2b, Ribavirin
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2013-11-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00724893?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00724893-68a39148